WO2013040547A3 - Compounds and methods of immunization with tumor antigens - Google Patents

Compounds and methods of immunization with tumor antigens Download PDF

Info

Publication number
WO2013040547A3
WO2013040547A3 PCT/US2012/055743 US2012055743W WO2013040547A3 WO 2013040547 A3 WO2013040547 A3 WO 2013040547A3 US 2012055743 W US2012055743 W US 2012055743W WO 2013040547 A3 WO2013040547 A3 WO 2013040547A3
Authority
WO
WIPO (PCT)
Prior art keywords
seq
methods
immunization
compounds
tumor antigens
Prior art date
Application number
PCT/US2012/055743
Other languages
French (fr)
Other versions
WO2013040547A2 (en
Inventor
Kate Rittenhouse-Olson
Susan MOREY
Julia ABDULLAH
Adel ALMOGREN
Jamie Heimburg MOLINARO
Original Assignee
The Research Foundation Of State University Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Research Foundation Of State University Of New York filed Critical The Research Foundation Of State University Of New York
Publication of WO2013040547A2 publication Critical patent/WO2013040547A2/en
Publication of WO2013040547A3 publication Critical patent/WO2013040547A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast

Abstract

Provided are compositions and methods for prophylaxis and/or therapy of cancer. The method involves administering to an individual in need of prophylaxis and/or therapy of cancer a composition which contains tanned mammalian red blood cells complexed with one or more agent(s) that can be a peptide having any of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4, or asialoglycophorin, or Thomsen-Friedenreich antigen (TF-Ag). Also provided are compositions which contain tanned red blood cells complexes with the peptides, asialoglycophorin, TF-Ag, or combinations thereof.
PCT/US2012/055743 2011-09-15 2012-09-17 Compounds and methods of immunization with tumor antigens WO2013040547A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161535185P 2011-09-15 2011-09-15
US61/535,185 2011-09-15

Publications (2)

Publication Number Publication Date
WO2013040547A2 WO2013040547A2 (en) 2013-03-21
WO2013040547A3 true WO2013040547A3 (en) 2014-05-08

Family

ID=47884018

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/055743 WO2013040547A2 (en) 2011-09-15 2012-09-17 Compounds and methods of immunization with tumor antigens

Country Status (1)

Country Link
WO (1) WO2013040547A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022026621A1 (en) * 2020-07-29 2022-02-03 Sqz Biotechnologies Company Methods to stimulate immune responses to mutant ras using anucleate cells

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4320111A (en) * 1977-06-14 1982-03-16 American Home Products Corporation Immunologic compositions methods of preparation and use
WO1992021378A1 (en) * 1991-06-03 1992-12-10 Consiglio Nazionale Delle Ricerche Vaccines with erythrocytes as antigen carriers
US20060147371A1 (en) * 2003-10-31 2006-07-06 Tuszynski Jack A Water-soluble compound
US20070083334A1 (en) * 2001-09-14 2007-04-12 Compugen Ltd. Methods and systems for annotating biomolecular sequences
US20080148432A1 (en) * 2005-12-21 2008-06-19 Mark Scott Abad Transgenic plants with enhanced agronomic traits

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4320111A (en) * 1977-06-14 1982-03-16 American Home Products Corporation Immunologic compositions methods of preparation and use
WO1992021378A1 (en) * 1991-06-03 1992-12-10 Consiglio Nazionale Delle Ricerche Vaccines with erythrocytes as antigen carriers
US20070083334A1 (en) * 2001-09-14 2007-04-12 Compugen Ltd. Methods and systems for annotating biomolecular sequences
US20060147371A1 (en) * 2003-10-31 2006-07-06 Tuszynski Jack A Water-soluble compound
US20080148432A1 (en) * 2005-12-21 2008-06-19 Mark Scott Abad Transgenic plants with enhanced agronomic traits

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIAGIOTTI ET AL.: "Drug delivery by red blood cells.", IUBMB LIFE, vol. 63, no. 8, August 2011 (2011-08-01), pages 621 - 631 *
DATABASE UNIPROT 8 March 2011 (2011-03-08), retrieved from http://www.uniprot.org/uniprot/Q6LOW7.txt?version=40 accession no. 6LOW7_PICTO *
MUZYKANTOV ET AL.: "Drug delivery by red blood cells: vascular carriers designed by Mother Nature.", EXPERT OPIN DRUG DELIV., vol. 7, no. 4, 2010, pages 403 - 427, XP055088510, DOI: doi:10.1517/17425241003610633 *

Also Published As

Publication number Publication date
WO2013040547A2 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
PH12015502638A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
MX358224B (en) Pharmaceutical composition for treatment and/or prevention of liver cancer.
MX2014001370A (en) Cancer treatment and/or prevention drug composition.
MX2014008963A (en) Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine.
MX355074B (en) Diagnosis and treatment of cancer based on avl9.
NZ619576A (en) Compositions and methods for the treatment of infections and tumors
IN2014MN01781A (en)
MX360208B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX363136B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX360211B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
NZ606195A (en) Methods and compositions for liver cancer therapy
BR112012018951C8 (en) monoclonal antibody, pharmaceutical composition, pharmaceutical combination, use of an antibody, use of a pharmaceutical composition and use of a pharmaceutical combination
MX2012008999A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX340015B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX340016B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
PH12021551208A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
WO2014008206A3 (en) DIAGNOSTIC AND THERAPEUTIC POTENTIAL OF HLA-E MONOSPECIFIC MONOCLONAL IgG ANTIBODIES DIRECTED AGAINST TUMOR CELL SURFACE AND SOLUBLE HLA-E
MX2021012004A (en) Compositions and methods for preparing t cell compositions and uses thereof.
GB201019331D0 (en) Methods for the diagnosis and treatment of cancer based on AVL9
WO2013170263A3 (en) Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics
WO2013040547A3 (en) Compounds and methods of immunization with tumor antigens
WO2021198449A3 (en) Tumor antigens for liver cancer immunotherapy
WO2011090266A3 (en) Novel tumor antigen protein agr2 and tumor antigenic peptide thereof
WO2011150897A3 (en) Cancer therapy method

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12831561

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12831561

Country of ref document: EP

Kind code of ref document: A2